Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Spirapril
Другие языки:
Spirapril
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Trade names | Renormax |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50% |
Metabolism | converted to spiraprilat |
Elimination half-life | 30 to 35 hours |
Excretion | Hepatic and renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H30N2O5S2 |
Molar mass | 466.61 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Spirapril, sold under the brand name Renormax among others, is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.
It was patented in 1980 and approved for medical use in 1995.
Chemistry
Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment. However, data on its effect upon the renal function are conflicting.
External links
- Media related to Spirapril at Wikimedia Commons
ACE inhibitors ("-pril") |
|
---|---|
AIIRAs ("-sartan") |
|
Renin inhibitors ("-kiren") |
|
Dual ACE/NEP inhibitors | |
Neprilysin inhibitors | |
|